Related Experiment Video
Updated: Mar 29, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Treatment options in non-muscle-invasive bladder cancer after BCG failure
Nathan A Brooks1, Michael A O'Donnell1
1Department of Urology, The University of Iowa, Iowa, USA.
Abstract:
Bladder cancer is the ninth-most prevalent cancer worldwide. Most patients with urothelial cell carcinoma of the bladder present with non-muscle-invasive disease and are treated with bacillus Calmette-Guérin (BCG) intravesical therapy. Many of these patients experience disease recurrence after BCG failure. Radical cystectomy is the recommended treatment for high-risk patients failing BCG. However, many patients are unfit for or unwilling to undergo this procedure. We searched the published literature on the treatment of non-muscle-invasive bladder cancer (NMIBC) after BCG failure. We review current evidence regarding intravesical therapy with gemcitabine, mitomycin combined with thermo-chemotherapy, docetaxel, nab-paclitaxel, photodynamic therapy (PDT), BCG with interferon (IFN), and combination sequentially administered chemotherapy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Imaging Studies VI: Voiding Cystourethrography and Cystography
Tumor Immunotherapy
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi III: Medical Management

